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Efficacy, acceptability, and tolerability of all
available treatments for insomnia in the
elderly: a systematic review and network
meta-analysis
Samara MT, Huhn M, Chiocchia V, Schneider-Thoma J, Wiegand M,
Salanti G, Leucht S. Efficacy, acceptability, and tolerability of all
available treatments for insomnia in the elderly: a systematic review and
network meta-analysis.
Objectives: Symptoms of insomnia are highly prevalent in the elderly. A
significant number of pharmacological and non-pharmacological
interventions exist, but, up-to-date, their comparative efficacy and
safety has not been sufficiently assessed.
Methods: We integrated the randomized evidence from every available
treatment for insomnia in the elderly (>65 years) by performing a
network meta-analysis. Several electronic databases were searched up to
May 25, 2019. The two primary outcomes were total sleep time and
sleep quality. Data for other 6 efficacy and 8 safety outcomes were also
analyzed.
Results: Fifty-three RCTs with 6832 participants (75 years old on
average) were included, 43 of which examined the efficacy of one or
more drugs. Ten RCTs examined the efficacy of non-pharmacological
interventions and were evaluated only with pairwise meta-analyses
because they were disconnected from the network. The overall
confidence in the evidence was very low primarily due to the small
amount of data per comparison and their sparse connectedness. Several
benzodiazepines, antidepressants, and z-drugs performed better in both
primary outcomes, but few comparisons had data from more than one
trial. The limited evidence on non-pharmacological interventions
suggested that acupressure, auricular acupuncture, mindfulness-based
stress reduction program, and tart cherry juice were better than their
control interventions. Regarding safety, no clear differences were
detected among interventions due to large uncertainty.
Conclusions: Insufficient evidence exists on which intervention is more
efficacious for elderly patients with insomnia. More RCTs, with longer
duration, making more direct interventions among active treatments
and presenting more outcomes are urgently needed.
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Summations
• Several antidepressants, benzodiazepines, and z-drugs performed better than other drugs in improv-
ing total sleep time and sleep quality.
• For non-pharmacological interventions, there was some evidence of efficacy for acupressure, auricu-
lar acupuncture, mindfulness-based stress reduction program, and tart cherry juice in sleep quality,
but not in total sleep time.
• Regarding adverse events, no firm conclusions could be reached due to large uncertainty.
Limitations
• Despite the fact that we synthesized all available evidence, most estimates were uncertain because
there were few studies per intervention and the network was not so well connected.
• Non-pharmacological treatments were not compared to drugs in any of the identified trials; hence,
we were unable to evaluate their relative effects.
• Overall, the available evidence was scarce and of questionable quality.
Introduction
Approximately 50% of older adults complain
about symptoms of insomnia (1). Insomnia leads
to reduced quality of life (2, 3), impairments in
psychosocial and cognitive functioning, facilitates
other mental disorders like depressive disorders or
substance abuse (4, 5), and may increase the risk
for cardiovascular and metabolic diseases (6-9). It
is known that people suffering from insomnia have
higher use of healthcare services (10) and cause
higher costs thereby (11).
A broad range of pharmacological and non-
pharmacological interventions for sleep disorders
exists. Sedating drugs such as benzodiazepines or
the so-called z-drugs are still used very frequently
in the elderly population although the choice of
substance has changed over the last decades and
new substances have become available (12). Older
people, with their age-related changes in brain
structure and drug metabolism and their high rate
of comorbidities are especially susceptible to
adverse events of these substances. Adverse events
related to insomnia and sedating drugs are often
severe and include risk of falls and fractures, over-
sedation, and confusion (13-16). Therefore, several
authors suggest that non-pharmacological inter-
ventions should be considered as first-line treat-
ment options for insomnia in the elderly (17).
Non-pharmacological treatment options include
different approaches such as sleep hygiene, relax-
ation techniques, or cognitive behavioral therapy
that attempt to modify sleep-related cognitions
and behaviors (18), but also other interventions
such as acupuncture, music therapy, bright-light
therapy, or yoga.
The comparative efficacy and safety of this vari-
ety of newer and older pharmacological and non-
pharmacological interventions has not been suffi-
ciently assessed yet (12, 19). Few meta-analytical
evaluations exist, and these have been published at
least ten years ago (20, 21); thus, for most interven-
tions, an efficacy and safety appraisal is not avail-
able.
Aims of the study
It is currently unclear which of the available inter-
ventions should be preferred in terms of efficacy
and safety for the treatment of insomnia in the
elderly. Therefore, we decided to conduct a com-
prehensive systematic review of all currently avail-
able treatment options and assess their relative
effects via network meta-analysis (NMA).
Materials and methods
An a priori written study protocol was published
in PROSPERO [number: CRD42018106411] and
can be found in Appendix S2.
Participants and interventions
Our analysis included all randomized controlled
trials (RCTs) that examined treatment options for
insomnia in elderly patients (>65 years). All avail-
able interventions were included. Minimum dura-
tion of RCTs was set at 5 days for drug
interventions; for non-drug interventions, the
study duration criterion did not apply. No maxi-
mum duration of RCTs was set.
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Search strategy and selection criteria
We identified RCTs in elderly patients with insom-
nia through a comprehensive, systematic literature
search in MEDLINE, Embase, PsycINFO,
Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews
(CDSR), ClinicalTrials.gov, and WHO ICTRP up
to May 25, 2019 (Appendix S3). Moreover, we
inspected the reference lists of the included studies
and previous reviews on the same topic (20, 21).
We excluded cluster-randomized trials (22). Stud-
ies that demonstrated a high risk of bias for
sequence generation or allocation concealment
were excluded (23). If a trial was described as dou-
ble-blind but randomization was not explicitly
mentioned, we assumed that study participants
were randomized, and we excluded the trial in a
sensitivity analysis. Risk of bias in the included
studies was independently assessed by two review-
ers (M.T.S. and M.H.), using the Cochrane collab-
oration’s risk-of-bias tool (23). We sent emails to
the first and corresponding authors of all included
studies to ask for missing data.
Outcome measures and data extraction
The primary outcomes were (a) nocturnal total
sleep time measured in minutes and (b) sleep qual-
ity as measured by any validated self-rating scale,
for example, the Pittsburgh Sleep Quality Index
(24) or the Insomnia Severity Index (25).
Secondary outcomes were sleep onset latency
defined as the time taken to fall asleep measured in
minutes; number of nocturnal awakenings; noctur-
nal time awake after sleep onset defined as the total
minutes spent awake after sleep onset until the end
of sleep; daytime impairment measured by perfor-
mance tasks and self-reports such as the Epworth
Sleepiness Scale (26) or the Stanford Sleepiness
Scale (27); subjective well-being/quality of life
measured by any validated scale such as Short
Form-36 (SF-36) (28); polysomnographic or acti-
graphic recordings of the primary outcome ‘noc-
turnal sleep time total’ measured in minutes; drop-
outs due to any reason and due to adverse events;
total number of adverse events; and the occurrence
of important adverse events such as sedation and
subsequent impaired daytime-functioning, risk of
falls, paradoxical drug reactions, for example, agi-
tation or anxiety, dependency, cardiovascular
adverse effects (AEs), hematological AEs, and
endocrinological AEs.
When authors of original studies used imputa-
tion methods to handle missing data, these were
preferred over completers’ data. In crossover trials,
we used the first crossover phase to avoid the prob-
lem of carryover effects (29) if possible; otherwise,
we included the results as presented by the authors
if there was an adequate washout period between
the different phases, defined as a minimum of 5
times the elimination half-life of each drug (30).
Study selection and data extraction were per-
formed independently by at least two reviewers
(M.T.S., M.H.). Missing SDs were estimated from
P values or substituted by the mean SD of the
other included studies.
Statistical analysis
We performed pairwise meta-analyses and NMAs
in a frequentist setting using the R packages meta
(31) and netmeta (32). We used the random effects
model and assumed common heterogeneity across
all comparisons. For continuous outcomes, we pri-
marily used absolute numbers, for example, total
sleep time in minutes, and presented them as mean
differences (MDs). If different scales were used, as
for the assessment of sleep quality, the effect sizes
were calculated as Hedge’s g standardized mean
differences (SMDs). For binary outcomes, the
effect sizes were calculated as odds ratios (ORs).
Both types of effect sizes were presented in league
tables with their 95% confidence intervals (CIs).
To avoid redundancy with the tables, only large
and relatively precise associations are discussed in
the text. When possible, statistical inconsistency
was evaluated using the SIDE test that separates
indirect and direct estimates (33) and the design-
by-treatment interaction test to assess global
inconsistency in the network (34, 35). We assessed
the plausibility of the transitivity assumption by
examining if there were any important differences
between treatments in key study characteristics
that could be effect modifiers and we have planned
several subgroup analyses and meta-regressions.
The variables considered a priori were as follows:
(i) percentage of female participants, (ii) baseline
severity of the primary outcomes, (iii) study dura-
tion and (iv) sponsoring of pharmaceutical indus-
try and allegiance bias, that is, whether the
inventors of psychotherapy are also investigators
of a trial, and (v) in-patients versus out-patients.
Similarly, the following sensitivity analyses on the
primary outcomes were planned a priori: (i) fixed
effects instead of random effects model, (ii) exclu-
sion of open-label and single-blind studies, (iii)
exclusion of studies that did not use operational-
ized criteria to diagnose insomnia, (iv) exclusion of
studies that presented only completers analyses, (v)
exclusion of studies with high risk of bias in blind-
ing, missing outcome data, selective reporting and
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other biases, (vi) additional inclusion of studies
involving patients with secondary insomnia or
patients with severe somatic or psychiatric condi-
tions, as long as not all patients had the same
underlying disorder. We also re-analyzed the two
primary outcomes after grouping interventions in
their classes (e.g., benzodiazepines, antipsychotics,
antidepressants, psychotherapeutic interventions).
We planned to investigate the presence of small-
study effects for the primary outcomes by using a
comparison-adjusted funnel plot (36, 37). We
assessed the confidence in estimates of the primary
outcomes with the Confidence in Network Meta-
Analysis (CINeMA) framework and web applica-
tion (38-40).
Results
Description of included studies
We identified 53 RCTs with 6832 unique partici-
pants published from 1980 to 2019 through the lit-
erature search. The PRISMA flowchart is shown
in Fig. 1 and with details of all included studies in
Appendix S6. Of 43 studies that examined the effi-
cacy of one or more drugs, 31 had a placebo arm.
The drug involved in most comparisons was mela-
tonin (seven trials), followed by nitrazepam, tria-
zolam, and zolpidem (five trials each), whereas few
trials were available for most other drugs. The
remaining 10 RCTs examined the efficacy of other
interventions such as acupressure, auricular
acupuncture, magneto-auriculotherapy (MAT),
laser auriculotherapy (LAT), brief behavioral ther-
apy, hand bath plus massage, massage, mindful-
ness-based stress reduction program, tart cherry
juice, and therapeutic touch. These non-drug inter-
ventions were disconnected from the network for
all outcomes; therefore, only the results of their
pairwise meta-analyses are presented. For drug tri-
als, the network plots of eligible comparisons for
the primary outcomes are presented in Figs 2 and
3a and b (see below); network plots for secondary
outcomes are presented in Appendix S11. For each
outcome, some of the drugs, although included in
the systematic review, were not included in the net-
work meta-analysis because either they were not
connected to the network or they had no usable
data. For all interventions, pairwise meta-analytic
results are presented in Appendix S10.
Of 5209 patients with sex indicated, 3300 were
women (63.4%). The mean (SD) age of partici-
pants was 75.2 (4.2) years. The median trial dura-
tion was 21 days (range of 3 to 168). The
assessment of risk for bias is presented in
Appendix S7. The trial reports often did not
provide details about randomization procedures
and allocation concealment; three studies were sin-
gle-blind, three were open-label, one used a single-
blind design for two arms and open-label design
for the third arm, and the remaining studies were
double-blind. The mean drop-out rate was 8.4%
for the studies included in our systematic review,
and we found indication for high risk of bias for
selective reporting in 23 studies (44.9%).
Primary outcomes of NMA
The results of the pairwise meta-analyses and the
NMA for total sleep time are summarized in
Table 1. The NMA results were in accordance
with the pairwise results, when the later was avail-
able. Compared to placebo, total sleep time was
on average 62 min longer in patients in food sup-
plement (i.e., a specific combination containing
5 mg melatonin, 225 mg magnesium, and
11.25 mg zinc) (41), 50 min longer in patients in
diazepam, 40 min longer in promethazine and
propiomazine, 36 min longer in temazepam,
31 min longer in doxepin, and 24 min longer in
eszopiclone.
For sleep quality, two different subnetworks
were formed (Fig. 3a and b). The results of the
pairwise meta-analyses and the NMAs of the two
subnetworks were broadly in accordance and are
summarized in Tables 2 and 3. Ordered from the
most to the least effective intervention, food sup-
plement (SMD 1.90), propiomazine (1.77),
melatonin (0.71), temazepam (0.48), eszopi-
clone (0.38), and doxepin (0.35) outperformed
placebo with lower values indicating better sleep
quality.
Nevertheless, the majority of the estimates were
uncertain because there were few studies per inter-
vention and even fewer closed loops.
Consistency of the network and confidence in the estimates
(CINeMA)
Inconsistency of the networks was not measurable
since there were no or just one or two closed loops
of evidence in each network. The few studies avail-
able per comparison did not allow firm conclusions
about the absence of imbalance in effect modifica-
tion and in most comparisons only one study was
available (Appendix S4). Consequently, the plausi-
bility of the transitivity assumption could not be
evaluated. The assessment of confidence in the esti-
mates using CINeMA was very low, primarily due
to within-study bias and across-studies bias, impre-
cision, and the inability to evaluate the synthesis
assumptions (incoherence) (Appendix S12).
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Secondary outcomes of NMA
Sleep onset latency. The league table is presented
in Appendix S9.1. Ordered from the most to the
least effective, diazepam, propiomazine, promet-
hazine, doxepin, eszopiclone, temazepam,
chlormethiazole, ramelteon, and suvorexant per-
formed better, with their MDs ranging from 25
to 7 min shorter time taken to fall asleep com-
pared to placebo, but there was much uncertainty.
Number of nocturnal awakenings. The league table
is presented in Appendix S9.2. From the most to
the least effective, zolpidem, temazepam, propi-
omazine, and diphenhydramine outperformed
placebo, with their MDs ranging from 0.96 to
0.30, but estimates were very uncertain.
Nocturnal time awake after sleep onset. From the
most to the least effective, suvorexant, melatonin,
esmirtazapine, doxepin, zolpidem, and eszopiclone
were associated with less nocturnal time awake
ranging from 24 to 12 min compared to pla-
cebo (Appendix S9.3).
Daytime impairment. For this outcome, two differ-
ent subnetworks were formed (Appendices S9.4a
and b). In the first subnetwork, propiomazine per-
formed better than the other interventions
Databases searched: Medline, Embase,
Psycinfo, the Cochrane Central Register of 
Controlled Trials, Cochrane Database of 
Systematic Reviews (CDSR),
Clinicatrials.gov, WHO trial registry (last 
search 5/ 2019) resulted in 6616 records
Id
en
tif
ica
tio
n
Sc
re
en
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g
El
ig
ib
ili
ty
In
clu
de
d
4388 reports screened
3339 reports excluded after 
title and abstract 
1049 fulltexts
screened
Excluded for the following reasons:
• Not adequately randomized (50)
• Review (7)
• Wrong diagnosis (291)
• Not over 65 years old (512)
• Not marketed drug (25)
• Not adequate wash-out (6)
• Comparison of different doses (1)
• Too short duration (25)
• Ongoing (6)
• Awaiting assessment (25)
101 reports to 53 
studies
2228 records after elimination of duplicates
Fig. 1. PRISMA flow diagram.
[Colour figure can be viewed at wile
yonlinelibrary.com]
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(Appendix S9.4a). In the second subnetwork, no
important differences were detected due to large
uncertainty (Appendix S9.4b).
Quality of life. Only three studies provided useful
data for this outcome. Food supplement per-
formed better than placebo with an SMD of 0.61,
but there was large uncertainty (Appendix S9.5).
Polysomnographic/actigraphic recordings of nocturnal
sleep time total. From the most to the least effec-
tive, esmirtazapine, eszopiclone, and doxepin per-
formed better than placebo (MDs, 39.22, 25.53,
and 23.61 min, respectively, Appendix S9.6).
Drop-outs due to any reason and due to adverse
events. No important differences were detected in
drop-outs due to any reason or due to adverse
events between any of the interventions either in
the pairwise meta-analyses or in the NMA due to
large uncertainty (Appendices S9.7 and S9.8).
Total number of patients with adverse events and
important individual adverse events. The small
number of studies and the large uncertainty in the
results did not enable firm conclusions for these
outcomes as presented in Appendices S9.9–S9.13b.
Only for sedation, there was some evidence that
esmirtazapine performed worse than chlormethia-
zole, eszopiclone, and placebo (Appendix S9.14).
Pairwise meta-analyses of non-pharmacological inter-
ventions. The results of all pairwise meta-analyses
of all outcomes are presented in Appendix S10.
For non-pharmacological interventions, nine out
of ten included studies provided usable data. Acu-
pressure performed better than sham acupressure
in terms of sleep quality (SMD 1.58) and quality
of life (SMD 5.09); auricular acupuncture per-
formed better than its control in terms of sleep
quality (SMD 147.29) without showing more
drop-outs, but the quality of the single trial was
very low and the sample size small (n = 44) making
the results unreliable; no important differences
were detected between brief behavioral therapy
and self-monitoring in terms of total sleep time,
sleep quality, sleep onset latency, waking after
sleep onset, total sleep time by polysomnography,
Fig. 2. Network plot for the outcome
‘total sleep time’. The size of the nodes
corresponds to the number of
participants assigned to each treatment.
Treatments with direct comparisons are
linked with a line; its thickness
corresponds to the number of trials
evaluating the comparison. [Colour
figure can be viewed at wileyonlinelibra
ry.com]
(a) (b)
Fig. 3. (a) Subnetwork plot 1 for the outcome ‘sleep quality’. The size of the nodes corresponds to the number of participants
assigned to each treatment. Treatments with direct comparisons are linked with a line; its thickness corresponds to the number of tri-
als evaluating the comparison. (b) Subnetwork plot 2 for the outcome ‘sleep quality’. The size of the nodes corresponds to the num-
ber of participants assigned to each treatment. Treatments with direct comparisons are linked with a line; its thickness corresponds
to the number of trials evaluating the comparison. [Colour figure can be viewed at wileyonlinelibrary.com]
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number of nocturnal awakenings, and total drop-
outs; similarly, no important differences were
detected between laser auriculotherapy (LAT),
magneto-auriculotherapy (MAT), and their combi-
nation in any of the examined outcomes (e.g., total
sleep time, sleep quality, sleep onset latency, wak-
ing after sleep onset, total sleep time by actigraphy,
quality of life, and total drop-outs); massage had
comparable drop-outs with no intervention; mind-
fulness-based stress reduction program performed
better than waitlist in terms of sleep quality (SMD
1.04) and daytime impairment (SMD 0.62),
with no observed difference in drop-outs; tart
cherry juice performed better than artificial juice in
terms of sleep quality (SMD 0.51) and time
awake after sleep onset (MD 17.00 min), but no
differences were detected in terms of total sleep
time, sleep onset latency, and drop-outs; no impor-
tant differences were detected between therapeutic
touch, mimic therapeutic touch, and no interven-
tion in terms of sleep quality. Side-effects were not
reported in any of the non-pharmacological inter-
ventions.
Meta-regression and sensitivity analyses for the pri-
mary outcome. Subgroup, meta-regression, and
some of the sensitivity analyses were not under-
taken due to insufficient data. Removing cross-
over studies or adding studies with
psychogeriatric patients did not substantially
change the results (Appendices S8.1 and S8.2
respectively). A further sensitivity analysis, com-
paring interventions as groups if possible,
showed that, for total sleep time, the most to
the least effective interventions were food sup-
plement, benzodiazepines, chlormethiazole,
antidepressants, and z-drugs (on average 62, 41,
40, 27, and 24 min longer sleep time than pla-
cebo, respectively), whereas, for sleep quality,
food supplement, chlormethiazole, melatonin
and melatoninergic agonists, benzodiazepines,
antihistamines, z-drugs, and antidepressants per-
formed better (SMDs 1.90, 0.93, 0.70,
0.53, 0.41, 0.31, and 0.29, respectively,
Appendix S8.3).
Small-study effects and publication bias. Compar-
ison-adjusted funnel-plots were not produced as
they would not be meaningful because compar-
isons included three studies at most.
Discussion
This is the first evidence synthesis which evaluated
all pharmacological and non-pharmacological
interventions in older patients with insomnia1
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including 53 studies, a large number of patients
(i.e., 6832), and assessing a total of 16 efficacy and
safety outcomes.
For the pharmacological interventions, we
found that food supplement (i.e., containing mela-
tonin, magnesium, and zinc), propiomazine, tema-
zepam, doxepin, and eszopiclone improved total
sleep time and sleep quality more than placebo.
Diazepam and promethazine were better than pla-
cebo in sleep duration and melatonin in sleep qual-
ity.
Few trials examined total sleep time with non-
pharmacological interventions and none found an
important effect. In terms of sleep quality, which
could be considered as a more subjective outcome,
acupressure, auricular acupuncture, mindfulness-
based stress reduction program, and tart cherry
juice performed better than their controls.
Regarding safety, no differences were detected
among interventions in any of the various outcomes
due to small sample sizes and resulting large uncer-
tainty; only for sedation, esmirtazapine was worse
than chlormethiazole, eszopiclone, and placebo.
In our meta-analysis, broad inclusion criteria
were applied for example insomnia or sleep disor-
der as defined by the authors of individual studies
as long as all patients did not suffer from the same
comorbid medical condition, which is particularly
important for reasons of transitivity when con-
ducting a network meta-analysis. In addition, and
in contrast to previous reviews on the same topic
which also included younger patients (42-45), only
patients older than 65 were selected. In many
countries, the age of 65 is associated with marked
changes in life such as retirement or a loss of close
relatives. Moreover, nowadays, the physical health
of patients in their late 50s or early 60s often does
not differ from ‘general’ adults. In order to exam-
ine older patients who are clearly different from
‘general’ adults (usually defined in studies as 18–
65 years), we focused on an age group which
would be classified as geriatric by recent definitions
(46) including mainly an age of over 70. While such
patients are usually excluded from studies in the
general population, the mean age of the included
studies in our meta-analysis was 75.2 years with a
range of 68–87.
Owing to several limitations, our findings are
not definitive. First of all, few comparisons had
data from more than one trial limiting the robust-
ness of the results. Due to the low reliability of the
results, treatment hierarchies were not produced.
The trials in the network were not as well linked
(Figs 2 and 3, and Appendix S11) as in other
NMAs (47) and consistency could not be assessed
since there were none or very few closed loops per
network. Furthermore, few trials had a duration
longer than 3 weeks. In our analysis, although
many efficacy differences were shown, no differ-
ences in drop-outs or side-effects were identified,
but it is possible that trials of longer duration
would be needed for this reason. Up to 2005, FDA
recommended that drug treatment for insomnia
should not exceed 4 weeks, but since 2005, treat-
ment duration is not addressed (48). Also, non-
pharmacological treatments were disconnected
from the network and the available evidence was
scarce and of questionable quality. Moreover,
many other drug interventions, such as bro-
mazepam, mirtazapine, and quetiapine which are
routinely used to treat insomnia in the elderly, had
no available RCT. Finally, results from a meta-
analysis cannot be better than those of the studies
included. In our NMA, reporting bias was present
in a considerable number of studies highlighting
that one of the intrinsic difficulties of the insomnia
literature is the multitude of possible outcomes,
including subjective and polysomnographic
ones. There is an inevitable necessity of agreed-
upon core outcome sets in the studies of insomnia,
so that selective outcome reporting will be discour-
aged and the more adequate evidence synthesis
becomes possible.
At present, insufficient evidence exists on which
intervention is more efficacious for elderly patients
with insomnia. Cognitive behavioral therapy is the
standard first-line treatment for all adults with
insomnia, and especially in the elderly population
is considered preferable since it is considered to
have fewer side-effects (49), but evidence from
Table 3. Sleep quality: subnetwork 2
Chlormethiazole NA NA 0.40 (0.98 to 0.19) NA
0.85 (2.18 to 0.47) Loprazolam 0.02 (0.63 to 0.67) NA NA
0.83 (1.99 to 0.32) 0.02 (0.63 to 0.67) Nitrazepam 0.44 (0.56 to 1.43) 0.02 (0.44 to 0.48)
0.40 (0.98 to 0.19) 0.46 (0.73 to 1.65) 0.44 (0.56 to 1.43) Triazolam NA
0.81 (2.05 to 0.43) 0.04 (0.76 to 0.84) 0.02 (0.44 to 0.48) 0.41 (1.51 to 0.68) Zopiclone
Treatments are presented in an alphabetical order. Results of the network meta-analysis are presented in the left lower half and results from pairwise comparisons in
the upper right half, if available. Comparisons between treatments should be read from left to right and the estimate is in the cell in common between the column-defining
treatment and the row-defining treatment. In the left lower half, standardized mean differences (SMDs) lower than 0 favor the column-defining treatment, in the upper right half
SMDs lower than 0 favor the row-defining treatment. Cells in bold print indicate significant results NA=not available.
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RCTs is lacking. Our analysis suggests that more
trials, of longer duration, examining more inter-
ventions and several outcomes are warranted. The
evidence contributing to our findings is of low
credibility and hence results could change if further
studies become published.
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